Endocrinology

Friday, October 30, 2026

1

AGS Framework for Obesity Medications in Older Adults

2

Large Early eGFR Decline on SGLT2 Inhibitors Linked to Mortality in CKD

3

Nereus Reduced Semaglutide-Induced Vomiting in Phase 3 Trial

Thursday, October 29, 2026

1

Lilly Reports Retatrutide Outperformed Ozempic 2mg in Type 2 Diabetes

2

GLP-1 RA Prescribing in Older Adults With Diabetes and Cancer Tied Mainly to Metabolic Risk

Wednesday, October 28, 2026

1

SGLT2 Inhibitor Fills Rose in Guideline-Targeted Patients After 2019 ADA Update

2

Maternal Autoimmune Disease in Pregnancy Tied to Higher Offspring Type 1 Diabetes

Monday, October 26, 2026

1

SGLT2 Inhibitors Associated With Small Rise in Hemoglobin and Hematocrit

2

FDA Extends Awiqli Weekly Basal Insulin Approval to Children 10 and Older

Friday, October 23, 2026

1

Retatrutide Reduced Sleep Apnea Severity vs Placebo in Phase 3 TRIUMPH-OSA Trials

Wednesday, October 21, 2026

1

No New Semaglutide Safety Concerns in Type 2 Diabetes and CKD

Monday, October 19, 2026

1

FDA Approves Enspryng as At-Home Subcutaneous Treatment for Thyroid Eye Disease

Friday, October 16, 2026

1

Digital GLP-1RA Program Associated With 15.5% Mean Weight Loss

2

Diabetes Tied to More Limb Events and Deaths in Premature PAD

Thursday, October 15, 2026

1

Nonapproved Retatrutide Users on Reddit Report Appetite and Fatigue Symptoms

Wednesday, October 14, 2026

1

SGLT2 Inhibitors Reduce HF Hospitalization, CV Death, and Kidney Events in Type 2 Diabetes

Tuesday, October 13, 2026

1

Weight Loss With GLP-1 Therapies Tracks With Systolic BP Drops Across Trials

2

Menopause Marked by Abrupt Physiological Shifts at Final Menstrual Period

3

Many US Adults Still Above LDL-C Thresholds Despite 2-Decade Decline

Monday, October 12, 2026

1

GLP-1 Drugs: Novo Nordisk and Eli Lilly Face Lawsuits Over Vision Loss and Eye Damage

Thursday, October 08, 2026

1

Sustained Real-Time CGM Use Associated With Lower HbA1c, and UACR Reduction in High-Risk Type 2 Diabetes

2

CGM Time Above 140mg/dL Predicts Stage 3 Type 1 Diabetes Similarly to OGTT

3

Oral Semaglutide Initiation Climbed Quickly After Obesity Approval but Trailed Tirzepatide

4

Cancer Survivors With Diabetes Less Likely to Use Injectable GLP-1 RAs

Wednesday, October 07, 2026

1

ACP Guideline Recommends Hormonal Therapy as First-Line Treatment for Menopausal Vasomotor Symptoms

2

STOP-DM Model Predicts Short-Term Pancreatic Cancer Risk in Diabetes

Monday, October 05, 2026

1

Safiglipron Noninferior to Dapagliflozin for HbA1c Lowering in Phase 3 OUTSTAND-2

2

Long-Term Smoking Cessation Linked to Lower Risk of Diabetic Microvascular Complications

3

Iatrogenic Menopause Linked to Higher Cardiovascular Risk and Excess Mortality Before Age 45

Friday, October 02, 2026

1

REMODEL: Semaglutide Shows Secondary Kidney Signals Despite Null Coprimary Results

Loading